KRAS and leukemia: Titanium and lactoferrin-loaded nanomedicine could be a promising candidate for leukemia treatment via modifying that distinct KRAS, Hprt, JAK2, P53, SAT-2 and C-Myc mutations and restoring hemoglobin and iron levels in DMBA induced leukemic rat model.